Literature DB >> 18171212

Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital.

Christie Y Jeon1, Soo Hee Hwang, Jin Hong Min, D Rebecca Prevots, Lisa C Goldfeder, Hyeyoung Lee, Seok Yong Eum, Doo Soo Jeon, Hyung Seok Kang, Jin Hee Kim, Byoung Ju Kim, Dae Yeon Kim, Steven M Holland, Seung Kyu Park, Sang Nae Cho, Clifton E Barry, Laura E Via.   

Abstract

BACKGROUND: Extensively drug-resistant (XDR) tuberculosis (TB) is a major public health threat in South Korea.
METHODS: We analyzed baseline epidemiological data for 250 patients enrolled in an ongoing prospective observational study of TB at a large tertiary referral hospital in South Korea.
RESULTS: Twenty-six subjects with XDR TB were identified; all were patients who had previously received TB therapy. Cumulative previous treatment duration (range, 18-34 months; odds ratio [OR], 5.6; 95% confidence interval [CI], 1.0-59), number of previously received second-line anti-TB drugs (OR, 1.3; 95% CI, 1.1-1.5), and female sex (OR, 3.2; 95% CI, 1.1-8.3) were significantly associated with XDR TB in crude analyses. After controlling for other factors in a multivariable model, cumulative previous treatment duration remained significantly associated with XDR TB (OR, 5.8; 95% CI, 1.0-61). Subjects with XDR TB were more likely to produce culture-positive sputum at 6 months, compared with patients with non-multidrug resistant TB (risk ratio, 13; 95% CI, 5.1-53). Kanamycin resistance was found to be predictive of 6-month culture positivity after adjustment for ofloxacin and streptomycin resistance (risk ratio, 3.9; 95% CI, 1.9-11).
CONCLUSIONS: XDR TB was found to be associated with the cumulative duration of previous treatment with second-line TB drugs among subjects in a tertiary care TB hospital. Patients with XDR TB were more likely to not respond to therapy, and successful conversion of sputum culture results to negative was correlated with initial susceptibility to both fluoroquinolones and kanamycin but not to streptomycin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171212     DOI: 10.1086/524017

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

2.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

3.  Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria.

Authors:  Marvin J Miller; Andrew J Walz; Helen Zhu; Chunrui Wu; Garrett Moraski; Ute Möllmann; Esther M Tristani; Alvin L Crumbliss; Michael T Ferdig; Lisa Checkley; Rachel L Edwards; Helena I Boshoff
Journal:  J Am Chem Soc       Date:  2011-01-28       Impact factor: 15.419

Review 4.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

Review 5.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

6.  Evolution and transmission patterns of extensively drug-resistant tuberculosis in China.

Authors:  Feifei Wang; Lingyun Shao; Xiaoping Fan; Yaojie Shen; Ni Diao; Jialin Jin; Feng Sun; Jing Wu; Jiazhen Chen; Xinhua Weng; Xunjia Cheng; Ying Zhang; Wenhong Zhang
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

Review 7.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

8.  Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea.

Authors:  Isdore Chola Shamputa; Jongseok Lee; Caroline Allix-Béguec; Eun-Jin Cho; Ji-im Lee; Vignesh Rajan; Eun Gae Lee; Jin Hong Min; Matthew W Carroll; Lisa C Goldfeder; Jin Hee Kim; Hyung Seok Kang; Soohee Hwang; Seok-Yong Eum; Seung Kyu Park; Hyeyoung Lee; Philip Supply; Sang-Nae Cho; Laura E Via; Clifton E Barry
Journal:  J Clin Microbiol       Date:  2009-12-16       Impact factor: 5.948

Review 9.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

Review 10.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.